⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PULM News
Pulmatrix, Inc. Common Stock
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
prnewswire.com
PULM
Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain
globenewswire.com
PULM
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
prnewswire.com
PULM